Vioxx Class Action Resources

Slater & Gordon books $10m Vioxx writedown
Slater & Gordon shares fall after it says it will book a $10m non-cash writedown on its Vioxx class action.

Slater & Gordon fail in Vioxx appeal
Law firm fails in bid for client to appeal decision on class action. 11 May 2012 1:20 PM

The Vioxx body count
Back in 2004, when Merck took Vioxx off the market, I remember reading that investigators believed the drug may have been responsible for as many as 50,000 deaths from heart attacks and strokes. 50,000! That must be a typo, I remember thinking, because, while the number appeared in various accounts, nobody seemed too upset about it.

Merck Australia’s Win in Vioxx Ruling Is Upheld by Court
Merck & Co. (MRK) isn’t liable in Australia for heart risks associated with the Vioxx painkiller, the country’s top court ruled, upholding an appeal of the first trial decision outside the U.S.

Vioxx Killed Half a Million? The Facts Are Grim.
It’s looking more and more likely that the Merck painkiller Vioxx, the blockbuster drug suspected of having caused more than 55,000 deaths from stroke and heart attack before being withdrawn from the market in 2004, actually killed many more people than we previously thought. While conducting research on America’s media coverage of the Vioxx scandal, publisher of The American Conservative Ron ...

Nerves send market to lower close
The Australian sharemarket finished the week on a losing note after US banking giant JP Morgan shocked investors by admitting to a $US2 billion derivatives trading loss, compounding the nervous tone from Greece’s protracted sovereign debt and political crisis.

European swings leave market on edge
Market watchers were kept on edge this week by political news from a troubled Europe.

Markets Live: Big weekly loss loom
Australian shares end down 2.5% for the week, the worst weekly since the end of November 2011.

Bad US news hits local sharemarket
THE Australian share market closed the week lower after bad news about the largest bank in the US, JPMorgan Chase.